Zyprexa Could Gain From CATIE Cost/Benefit Analysis, Lilly Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Forthcoming cost-effectiveness analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness study could prove to be a boon for Zyprexa because of reduced hospitalization with Lilly’s atypical antipsychotic.
You may also be interested in...
Monthly Schizophrenia Treatment Cost 20%-30% Lower With First-Generation Drug
Catie research published in the American Journal of Psychiatry shows that treatment with older drugs may be less expensive but just as effective.
Monthly Schizophrenia Treatment Cost 20%-30% Lower With First-Generation Drug
Catie research published in the American Journal of Psychiatry shows that treatment with older drugs may be less expensive but just as effective.
Lilly Knocks On Wood: Transition of Zyprexa Dual Eligibles Moves Along Smoothly
Lilly says that it is not hearing any "anecdotal stories" regarding troubles with transitioning dual eligibles taking the atypical antipsychotic to Medicare.